GTC Biotherapeutics (fka GTCB)

[DewDiligence]

ImClone clearly believes in ADCC. Check out this
excerpt from one of IMCL’s ASCO 2007 PR’s:

http://biz.yahoo.com/bw/070605/20070605006223.html?.v=1

>>
Like its marketed product ERBITUX® (cetuximab), the monoclonal antibodies in the ImClone pipeline are all type 1 immunoglobulin G (IgG1) antibodies. In vitro, IgG1 antibodies elicit antibody-dependent cellular cytotoxicity (ADCC), which can kill cancer cells and may contribute to their overall therapeutic effects.
<<

As previously noted (#msg-19999027), AMGN’s Vectibix, which targets the same receptor as Erbitux, does not have ADCC functionality. It also doesn’t seem to work as well as Erbitux, and that’s probably not a coincidence.